7D). The results demonstrated that analysis of scAb GLAF-1 in the serum could also be used as a pharmacokinetic marker for virus colonization and persistence in GLV-1h109-injected xenograft mice. == Colonization of GLV-1h109 Sivelestat in STSA-1 Tumor Xenograft Significantly Inhibits Development of Tumor Vasculature == STSA-1 cells express 916 times more VEGF than DT08/40 cells as well as expression of scAb GLAF-1 was higher in STSA-1 xenografts than DT08/40 xenografts. anti-tumor and immunological effects resulting in the significant reduction of tumor growth in comparison to untreated control mice. Furthermore, tumor-specific virus infection led to a continued production of functional scAb GLAF-1, resulting in inhibition of angiogenesis. Overall, the GLV-1h109-mediated cancer therapy and production of immunotherapeutic anti-VEGF scAb may open the way for combination therapy concept i.e. vaccinia virus mediated oncolysis and intratumoral production of therapeutic drugs in canine cancer patients. == Introduction == Cancer is Sivelestat the leading cause of disease-related death in dogs worldwide ([1], National Canine Cancer Foundation). Incidence of cancer ranges from 1 to 2% in the canine population and is currently the leading cause of deaths in dogs older than 10 years[1][2]. The major treatment options available for canine cancers include surgery, radiation therapy, chemotherapy, hyperthermia and photodynamic therapy. Despite progress in the diagnosis and treatment of advanced canine cancer, overall patient treatment outcome has not substantially improved in the past. Therefore, the development of new therapies for advanced canine cancer is a high priority. One of the most promising novel cancer therapies is oncolytic virotherapy. This method is based on the capacity of oncolytic viruses (OVs) Sivelestat to preferentially infect and lyse cancer cells without causing excessive damage to surrounding normal tissues. Several oncolytic viruses including various human and canine adenoviruses, canine distemper virus (CDV) and vaccinia virus strains have been successfully tested for canine cancer therapy in preclinical settings (for review see[3]). In this study, we analyzed the therapeutic potential of the oncolytic vaccinia virus GLV-1h109 strain in two different xenograft models based on canine soft tissue sarcoma STSA-1 cells[4]and canine prostate carcinoma DT08/40 cells[5]. GLV-1h109 virus was derived from the oncolytic vaccinia virus GLV-1h68[6]by replacinglacZgene (beta-galactosidase) with GLAF-1 protein encoding gene atJ2Rlocus[7]. Theglaf-1gene Sivelestat encodes the single chain anti-VEGF antibody. GLAF-1 protein, comprises of an Ig light chain leader sequence[8], the VHchain sequence of the G631 antibody[9], a (G4S)3linker sequence, the VLchain sequence of the G631 antibody[9], and a C-terminal DDDDK sequence[7]. The G631 antibody binds both murine (mu) and human (hu) vascular endothelial growth factor (VEGF) with high affinity[9]. The GLAF-1 antibody encoded by VACV strain GLV-h109 is expressed under the control of the vaccinia virus synthetic late (SL) promoter and also recognizes specifically mu and huVEGF[7]. However, cross reactivity of GLAF-1 with VEGF protein from other species was not known. VEGF or VEGF-A is a potent regulator Sivelestat of angiogenesis and therefore several anti-VEGF strategies have been developed for the treatment of human and canine tumors[10][11],[12]. One of the best characterized strategies is the VEGF blockade using the humanized anti-VEGF monoclonal antibody (mAb) bevacizumab (avastin). However, despite very promising preclinical results, bevacizumab has not been shown to provide a benefit in patients with breast cancer (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm279485.htm) or when used in Rabbit Polyclonal to Smad2 (phospho-Ser465) combination with chemotherapy for the treatment of colorectal cancer and non-small-cell carcinoma in humans[13]. The molecular and cellular events underlying resistance to anti-VEGF antibody-based therapy are not completely understood[14]. However, the lack of efficacy of bevacizumab after systemic treatment in patients may be at least attributable to the poor penetration of this antibody into the tumor tissue and metastases. Therefore, new methods or vectors allowing more specific delivery of the anti-VEGF antibodies into the tumor tissue are urgently necessary. We have already shown that the recombinant Vaccinia virus strains (VACV) expressing the GLAF-1 antibody exhibited enhanced tumor inhibition and therapeutic potency, which was comparable to the results seen in combination therapy with separately injected bevacizumab and the parental virus.